Eye & ENT Hospital of Fudan University
Organization-level profile for a sponsor, institution, collaborator, or mixed-role entity. These profiles are separated from the primary industry company index when appropriate.
Programs by Stage
Trial / Program Status
Modality Mix
Indication Coverage
Program Types
Population Tags
Strong-Evidence Records
0 recordsChecked Records With Caveats
7 checked · 0 open checksCRISPR/Cas13 RNA base-editing therapy delivered by unilateral intracochlear injection for OTOF p.Q829X mutation-associated hearing loss.
Academic trials of short-term oral prednisone regimens, with ginkgo biloba co-therapy/comparator, for acute subjective tinnitus.
Mixed academic tinnitus study cluster where ginkgo biloba extract was used as adjunct/comparator in acute tinnitus prednisone studies and as medication comparator in a chronic tinnitus rTMS trial.
Recruiting investigator-led study evaluating intracochlear EH002 gene therapy for congenital deafness caused by OTOF mutations, with dose-escalation cohorts and safety, tolerability, and preliminary efficacy endpoints.
Academic Phase 2 study evaluating glucocorticoid delivery through the round window membrane for profound or complete sudden sensorineural hearing loss. The study compares intracochlear triamcinolone acetonide, intracochlear dexamethasone, and intratympanic dexamethasone; these arms represent one route-and-steroid comparison study rather than separate commercial programs.
Randomized study comparing oral prednisone with intratympanic methylprednisolone for idiopathic sudden sensorineural hearing loss with vestibular dysfunction.
Intracochlear triamcinolone or dexamethasone through the round-window membrane, compared with intratympanic dexamethasone approaches, as salvage treatment for total sudden sensorineural hearing loss.